The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Dosage Regimen For A S1P Receptor Agonist - EP3453387

The patent EP3453387 was granted to Novartis on Jun 3, 2020. The application was originally filed on Dec 21, 2009 under application number EP18201062A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3453387

NOVARTIS
Application Number
EP18201062A
Filing Date
Dec 21, 2009
Status
Granted And Under Opposition
May 1, 2020
Publication Date
Jun 3, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMM & WITTKOPPMar 3, 2021HAMM & WITTKOPPWITHDRAWN
LABORATORIOS LICONSAMar 3, 2021DR SCHONWITHDRAWN
VON SEEBACHMar 3, 2021HAMM & WITTKOPPWITHDRAWN

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0627406
DESCRIPTIONWO0218395
DESCRIPTIONWO03097028
OPPOSITIONWO2009115954
OPPOSITIONWO2010072703
OPPOSITIONWO2010075239
SEARCHWO2009115954
SEARCHWO2009155475

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents